Ascletis Pharma Inc. (OTCMKTS:ASCLF) Short Interest Update

Ascletis Pharma Inc. (OTCMKTS:ASCLF) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 593,545 shares, a growth of 30.0% from the January 15th total of 456,545 shares. Based on an average daily volume of 3,532 shares, the short-interest ratio is currently 168.0 days. Based on an average daily volume of 3,532 shares, the short-interest ratio is currently 168.0 days.

Ascletis Pharma Stock Performance

Shares of ASCLF stock opened at $2.10 on Wednesday. Ascletis Pharma has a 12-month low of $0.62 and a 12-month high of $2.29. The firm’s 50 day moving average is $1.77 and its 200 day moving average is $1.60.

Ascletis Pharma Company Profile

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).